ReviewThe journal of headache and pain2026
Current landscape of migraine care with expert consensus from East Asia.
Review in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a debilitating neurovascular disorder affecting over one billion people globally. While reported prevalence in Asia is lower than in Western countries, significant regional variations and unique clinical presentations necessitate a tailored approach to management. From the Advisory Board Meeting of the East Asian Network for Migraine, expert insights and current literature from China, Japan, South Korea, and Taiwan were synthesized to establish a unified perspective on the epidemiological and sociocultural contexts of the region. Patients in these East Asian countries exhibit distinct clinical features, such as a lower frequency of migraine with aura and photophobia, but a higher incidence of osmophobia compared to Western populations. Despite these clear phenotypic differences, significant gaps in care persist. Acute treatments like triptans remain underutilized, and while emerging CGRP-targeting therapies show promise, their adoption is hindered by high costs and limited accessibility. Furthermore, the region faces critical challenges, including a lack of region-specific clinical trials, culturally appropriate assessment tools, and unified clinical guidelines. Optimizing migraine care in East Asia requires a shift toward personalized, culturally sensitive strategies. Experts reached a consensus on the urgent need for collaborative research to address existing disparities and improve patient outcomes. By aligning clinical practice with the unique sociocultural landscapes of these nations, this statement provides a foundational framework for enhanced policy development and improved migraine management across East Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.